Amgen’s Bkemv is the first interchangeable biosimilar to Soliris to treat certain rare diseases. The treatment of patients ...
The U.S. Food and Drug Administration approved on Tuesday Amgen's Bkemv, the first biosimilar to AstraZeneca's rare blood ...
Uplizna also hit the target on a number of secondary measures, including: annualised flare rate; flare-free, treatment-free ...
Amgen Inc (NASDAQ:AMGN) announced topline results from its Phase 3 trial evaluating the efficacy and safety of Uplizna ...
Amgen said on Wednesday its drug helped to reduce the risk of flares in patients with an immune system-related condition, ...
Amgen has made waves in the biosimilar field in recent years with its U.S.-first Humira biosim launch last year and its ...
The CD19-targeted rare disease medicine Uplizna was one of the crown jewels in Amgen’s $27.8 billion buyout of Horizon ...
Amgen Inc. (NASDAQ:AMGN) has recently been in the news due to its involvement in the promising obesity drug market. Analysts ...
Uplizna therapy reaches main goal in Phase 3 trial for IgG4-RD, cutting the risk of flare by 87% with no new safety events.
The FDA has made two approvals this week: the first interchangeable biosimilar of Soliris and another indication for Breyanzi ...
The FDA's vaccine advisory panel voted to recommend that this fall’s Covid-19 shots should be updated to target Omicron’s ...